RT Book, Section
A1 Slain, Douglas
A2 Sutton, S. Scott
SR Print(0)
ID 7252384
T1 Chapter 28. Invasive Fungal Infections
T2 McGraw-Hill's NAPLEX® Review Guide
YR 2011
FD 2011
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-175562-7
LK accesspharmacy.mhmedical.com/content.aspx?aid=7252384
RD 2024/04/25
AB Invasive  fungal  infections  are  associated  with  significant  morbidity  and  mortality  and  occur  most  frequently  in  immunocompromised  patients.1Candida  species  represent  the  fourth  most  common  cause  of  bloodstream  infections  in  hospitalized  patients.2  Over  the  past  decade,  the  field  of  clinical  mycology  has  changed  dramatically  and  there  has  been  a  doubling  of  licensed  medications  available  for  systemic  fungal  infections.  Advances  in  medical  technology,  including  organ  and  bone  marrow  transplantation,  cytotoxic  chemotherapy,  the  widespread  use  of  indwelling  IV  catheters,  and  the  increased  use  of  broad-spectrum  antibiotics  have  contributed  to  the  increase  of  fungal  infections.